HCP Live
Contagion LiveCGT LiveNeurology LiveHCP LiveOncology LiveContemporary PediatricsContemporary OBGYNEndocrinology NetworkPractical CardiologyRheumatology Netowrk
  • MJHLS Brand Logo

© 2022 MJH Life Sciences™ , NeurologyLive – Clinical Neurology News and Neurology Expert Insights. All rights reserved.

Americas Committee for Treatment and Research in Multiple Sclerosis

The Americas Committee for Treatment and Research in Multiple Sclerosis (ACTRIMS) Forum is a translational science meeting focusing on scientific discoveries made in multiple sclerosis (MS) to advance the understanding of research and clinical care of patients with MS.

Where Tolebrutinib and Other BTK Inhibitors Fit in the MS Treatment Landscape: Jiwoh Oh, MD, PhD

March 15, 2022

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed how investigational BTK inhibitors will be used among an ever-growing MS treatment toolbox. [WATCH TIME: 3 minutes]

Outlining Areas of Unmet Need and Next Steps for Research in MS

March 13, 2022

Speaking on his own presentation on economic burden in MS, Bruce Bebo, PhD, further shared his thoughts on areas of unmet need and the potential relationship of Epstein-Barr virus and MS.

Serum GFA Identified as a Biomarker for NMOSD, sNfL as a Predictor of Poor Post-Attack Outcomes

March 12, 2022

A systematic literature review of randomized controlled trials in neuromyelitis optica spectrum disorder was performed, with 7 studies identified and 2 used in analyses.

Autologous Hematopoietic Stem Cell Transplantation in Multiple Sclerosis Is Safe, Efficacious Over Long-Term

March 11, 2022

Investigators noted the long-term cost-effectiveness and safety of this approach, as it does not require the regular use of disease-modifying therapies.

Overview of Tolebrutinib’s Positive 18-Month Data in Relapsing MS: Jiwoh Oh, MD, PhD

March 10, 2022

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the tolebrutinib’s mechanism of action, and new data presented at ACTRIMS Forum 2022. [WATCH TIME: 4 minutes]

Addressing ‘Staggering’ Economic Burden for Patients With Multiple Sclerosis

March 10, 2022

Bruce Bebo, PhD, outlined findings from a recent analysis presented at ACTRIMS Forum 2022, with investigators concluding costs associated with the disease have previously been underestimated.

NeuroVoices: Jiwoh Oh, MD, PhD, on Radiologically Isolated Syndrome as a Precursor to MS

March 09, 2022

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital provided insight on the use of biomarkers to improve management of RIS and uncover more as it relates to MS.

No Greater Risk of Serious COVID-19, Severe Outcomes Linked to Cladribine Treatment

March 08, 2022

Data provide an update to the post-approval safety profile of cladribine tablets in patients with relapsing MS in reference to COVID-19 infections.

The Need for Guidelines on the Management of Radiologically Isolated Syndrome: Jiwoh Oh, MD, PhD

March 08, 2022

The staff neurologist and medical director of the Barlo Multiple Sclerosis Program at St Michaels Hospital discussed the lack of guidelines for patients with RIS and the research efforts needed going forward to establish them.

MS Relapses, Health Care Utilization Greatest Among COVID-19 Vaccinated Patients Treated With Ocrelizumab, Fingolimod

March 07, 2022

Previously reported data show patients with multiple sclerosis treated with anti-CD20s have reduced response to COVID-19 vaccines, but there has been limited research on MS outcomes among vaccinated patients.